In an era of personalized medicine with tailored treatment expectations, we need smaller trials in homogeneous populations with highevent rates. Conclusive results from such trials can be used to help individualize treatments for patients with asthma according to phenotype and age.

In moderate-to-severe asthma, as-needed albuterol-budesonide reduced severe exacerbations vs. albuterol alone

Marco Confalonieri
2022

Abstract

In an era of personalized medicine with tailored treatment expectations, we need smaller trials in homogeneous populations with highevent rates. Conclusive results from such trials can be used to help individualize treatments for patients with asthma according to phenotype and age.
File in questo prodotto:
File Dimensione Formato  
Annals Journal Club.pdf

non disponibili

Descrizione: Articolo
Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 974.42 kB
Formato Adobe PDF
974.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3030480
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact